Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech ...

Viking Therapeutics has more than one highly promising clinical-stage candidate. It doesn't face much in the way of financial barriers to implementing its strategy. It's also a very appealing partner ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...

Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The biotech recently revealed promising data from trials of its oral weight ...